The agents previously approved for systemic adjuvant treatment of melanoma included dacarbazine, cisplatin, vinblastine, IL-2, interferon alfa-2b and pegylated interferon,47,48 which showed inconsistent improvements in OS along with substantial toxic effects49,50. The gene discussed is IL2; the disease is melanoma.